Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Participation Deadline: 12/01/2027
Apply Now

Description

The total duration of the study will be 6 years (4 years of patient enrollment and 2 additional years of clinical follow-up). Assessment for disease recurrence and survival will be conducted every 6 months (with a phone call/secure email, medical records or follow up visit) from the end of treatment for a total of 2 years, until the completion of the trial or until documented disease recurrence.